Since then the share price has fallen back to $40 on the back of questions over this episode as well as weak trading results and important progress made by competitors such as Gilead in the company’s other main market, Hepatitis C.
Call to Action:
Read why leading UK medical scientist David Grainger and thousands of others have signed the petition to get the NHS to agree a deal with Vertex and, while you are there, sign it yourself.
Read & Sign: Campaign for Kalydeco Petition - Comments by David Grainger
David Grainger is a Venture Partner at Index Ventures; former Director of the Translational Research Unit of the Papworth Hospital NHS Foundation Trust; and former Principal Investigator in the Department of Medicine at Cambridge University. He is also part of TCP Innovations Ltd, a leading life sciences consultancy; founder of a number biotech companies; and author of the widely-read DrugBaron blog on pharmaceutical and biotech industry news and @sciencescanner twitter feed.
Click here to read more of David's views on Kalydeco and pricing of new drugs for orphan diseases
Please also read my follow-up post on the lessons we can learn from Kaydeco and the bigger picture:
Spit It Out!: The Case for a Global CF Foundation?
Should the Cystic Fibrosis Foundation Invest $58M in Pfizer Research?, John LaMattina, Forbes.com, 28 Nov 2012